Business Wire

NY-CLARITY-AI

2.8.2022 14:02:12 CEST | Business Wire | Press release

Share
Clarity AI Named a Leader in ESG Ratings, Data, And Analytics Report by Independent Research Firm

Clarity AI announced today that they have been named a leader in “The Forrester New Wave™: ESG Ratings, Data, And Analytics, Q3 2022.” Clarity AI received a differentiated rating, the highest score possible across 7 of the 10 criteria evaluated: Analytics Capabilities, Standards Integrity, Presentation, Connections/Integrations, Execution Roadmap, Market Approach, and Product Vision.

“We are thrilled to be included in this report, and we thank our clients for making themselves available to Forrester for open, transparent discussions about Clarity AI and our product and strategy,” said Angel Agudo, VP of Product and Member of the Board at Clarity AI. “We believe we are bringing the very best product to market, and to see us land in the Leader section of this report is both validating and humbling for us.”

Forrester’s take on Clarity AI includes the following:

  • Offers strong analytics and user presentation capabilities. Clarity AI makes it easy for users to assess individual companies’ ESG-driven impact and benchmark it against peers (to support EU taxonomy-aligned reporting, for example). The web application is particularly well-designed and easy for users to navigate and explore.”
  • Is the best fit for companies that need to manage lots of ESG data. Many of Clarity AI’s financial services clients use it to model ESG data from a huge universe of companies and financial instruments in order to create and test new products and optimize portfolios.”

Additionally, Clarity AI clients, whom the analyst team at Forrester interviewed, had the following to say:

  • “They understood nuances that their competitors didn’t even know existed.”
  • “It’s very easy to see a company’s alignment with technical standards.”
  • “The process of connecting was seamless; it took only a month to get the API set up properly.”

A total of nine providers were evaluated in “The Forrester New Wave™: ESG Ratings, Data, And Analytics” report. Among the nine, the Forrester report cites that Clarity AI has the highest strategy score.

Mr. Agudo adds, “Forrester’s analysis provides a good view into the Clarity AI product vision and strategy that extends to our entire offering, which includes solutions and capabilities to cover Impact assessment, ESG risk assessment, carbon foot-printing, investment portfolio analysis, and the regulatory requirements, including associated reporting needs , associated with EU Taxonomy, SFDR and MiFID II, as well as the Paris Agreement (i.e., Net Zero) and the TCFD framework.”

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, companies, governments, and consumers. As of July 2022, Clarity AI’s platform analyzes more than 50,000 companies, 300,000 funds, 198 countries and 188 local governments – 2-3 times more than any other player in the market – and delivers data and analytics for investing, corporate research and reporting. Clarity AI has offices in North America, Europe and the Middle East, and its client network manages tens of trillions in assets under management. clarity.ai

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye